Retention Rates of Adalimumab, Etanercept and Infliximab as First and Second-Line Biotherapy in Patients With Rheumatoid Arthritis in Daily Practice
Clinical trial NCT01692899 · COMPLETED
Trial details
- NCT number
- NCT01692899
- Sponsor
- Pfizer
- Status
- COMPLETED
- Study type
- OBSERVATIONAL
- Start date
- 2011-06-01
- Primary completion
- 2011-09-01
- Enrollment
- 780
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.